Lasting Effect Consumer Pharma

Company Overview

Snapshot

Founded in March 2020 by David Tavor, Igal Pikovsky, and Eli Heldman, Lasting Effect Consumer Pharma operates with 1–10 employees. The company has raised $1.85 million across two funding rounds from three investors. In January 2023, the company secured a grant from the Israel Innovation Authority.

Business overview

Lasting Effect Consumer Pharma develops pharmaceutical therapeutics utilizing a proprietary buccal extended-release drug delivery system. This technology involves adhesive tablets designed to attach to the oral mucosa, facilitating the continuous administration of active ingredients either topically or systemically while bypassing the digestive tract. The company's solutions address challenges such as dysphagia and administration compliance, with key applications including saliva-stimulating treatments for dry mouth (xerostomia) and anti-bacterial formulations for gingivitis. Additionally, Lasting Effect offers a non-invasive solution for late-stage Parkinson’s disease, providing prolonged dopamine secretion as an alternative to continuous infusion pumps, thereby maintaining consistent therapeutic levels and enhancing patient care for chronic conditions within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Lasting Effect Consumer Pharma's core technology?

Lasting Effect Consumer Pharma develops pharmaceutical therapeutics based on a proprietary buccal extended-release drug delivery system. This system uses adhesive tablets that attach to the oral mucosa for continuous administration of active ingredients.

Which medical conditions does Lasting Effect Consumer Pharma's technology address?

The company's technology addresses conditions such as dry mouth (xerostomia) with saliva-stimulating treatments, gingivitis with anti-bacterial formulations, and late-stage Parkinson’s disease by providing prolonged dopamine secretion.

When was Lasting Effect Consumer Pharma founded and by whom?

Lasting Effect Consumer Pharma was founded in March 2020 by David Tavor, Igal Pikovsky, and Eli Heldman.

What was a significant funding event for Lasting Effect Consumer Pharma?

In January 2023, Lasting Effect Consumer Pharma received a grant from the Israel Innovation Authority.

What is the total capital raised by Lasting Effect Consumer Pharma?

Lasting Effect Consumer Pharma has raised a total of $1.85 million across two funding rounds.